Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions
暂无分享,去创建一个
D. Wallach | D. Aderka | M. Greaves | P. ETTEHADI | M. W. GREAVES | D. WALLACH | D. ADERKA | R. D. R. CAMP | R. Camp | P. Ettehadi | M. Greaves
[1] T. Espevik,et al. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.
[2] G. Adolf,et al. Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity. , 1992, Cytokine.
[3] R. Smith,et al. The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.
[4] I. Colditz,et al. The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin. , 1992, Immunology.
[5] M. Wadhwa,et al. Cytokines in skin lesions of psoriasis. , 1990, Cytokine.
[6] S. Akira,et al. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF) , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] D. Macdonald,et al. Endothelial leucocyte adhesion molecule‐1 (ELAM‐1) expression in cutaneous inflammation , 1991, The British journal of dermatology.
[8] A. Meager,et al. Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). , 1987, Hybridoma.
[9] D. Wallach,et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.
[10] F. Balkwill,et al. Tumour necrosis factor. , 1989, British medical bulletin.
[11] D. I. Stuart,et al. Structure of tumour necrosis factor , 1989, Nature.
[12] D. Macdonald,et al. Cutaneous lymphocyte trafficking in the inflammatory dermatoses , 1992, The British journal of dermatology.
[13] A. Meager,et al. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. , 1988, Clinical and experimental immunology.
[14] H. Schoenfeld,et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[15] James T. Elder,et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. , 1991, The American journal of pathology.
[16] A. Mantovani,et al. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. , 1987, Journal of immunology.
[17] D. de Silva. Tumour necrosis factor , 1990, The Ceylon medical journal.
[18] J. Voorhees,et al. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. , 1989, Journal of the American Academy of Dermatology.
[19] U. Gullberg,et al. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain. , 1992, European journal of cell biology.
[20] D. Wallach,et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. , 1991, Cancer research.